Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR; ROCKET AF Steering Committee and Investigators. Washam JB, et al. Among authors: mahaffey kw. Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6. Lancet. 2015. PMID: 25749644
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Mahaffey KW, et al. Am Heart J. 2002 Feb;143(2):242-8. doi: 10.1067/mhj.2002.120145. Am Heart J. 2002. PMID: 11835026
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, Ohman EM, Topol EJ, Califf RM, Van de Werf F, Armstrong PW; PARAGON-B Investigators. Kaul P, et al. Among authors: mahaffey kw. J Am Coll Cardiol. 2003 Feb 5;41(3):371-80. doi: 10.1016/s0735-1097(02)02824-3. J Am Coll Cardiol. 2003. PMID: 12575962 Free article. Clinical Trial.
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver Lee P, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM; ATBAT Investigators. Mahaffey KW, et al. J Invasive Cardiol. 2003 Nov;15(11):611-6. J Invasive Cardiol. 2003. PMID: 14608128
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, Gore J, Weaver WD, Longstreth WT Jr, Stebbins A, Lee KL, Califf RM, Topol EJ; Global Utilization of Streptokinase and tPA for Occluded Arteries-I Investigators. Kandzari DE, et al. Among authors: mahaffey kw. Am J Cardiol. 2004 Feb 15;93(4):458-61. doi: 10.1016/j.amjcard.2003.10.043. Am J Cardiol. 2004. PMID: 14969623
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Waters RE 2nd, Singh KP, Roe MT, Lotfi M, Sketch MH Jr, Mahaffey KW, Newby LK, Alexander JH, Harrington RA, Califf RM, Granger CB. Waters RE 2nd, et al. Among authors: mahaffey kw. J Am Coll Cardiol. 2004 Jun 16;43(12):2153-9. doi: 10.1016/j.jacc.2003.12.057. J Am Coll Cardiol. 2004. PMID: 15193673 Free article. Review.
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Ferguson JJ, et al. Among authors: mahaffey kw. JAMA. 2004 Jul 7;292(1):45-54. doi: 10.1001/jama.292.1.45. JAMA. 2004. PMID: 15238590 Clinical Trial.
635 results